Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test reliably screen for fetal genetic conditions?

NCT ID NCT04595201

Knowledge-focused Sponsor: Sequenom, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study follows 20,000 pregnant women who took a non-invasive prenatal test (NIPT) to see how accurately the test predicts fetal genetic conditions. Researchers will compare the test results with actual pregnancy outcomes to measure its sensitivity, specificity, and predictive value. The goal is to confirm how well NIPT works as a routine screening tool for pregnant women.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Non-invasive prenatal testing (NIPT), a blood test that screens for fetal genetic conditions
What this could lead to
If the test performs well, it could confirm NIPT as a reliable screening tool for pregnant women, helping them make informed decisions.
What could go wrong
This is an observational follow-up, not a treatment trial, so it won't change outcomes. Accuracy may vary across populations, and the study depends on available pregnancy outcome data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

20,000 people

The number who actually took part.

Started

Oct 2020

Finished

Sep 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The Study Population will consist of women 18 years of age and older who underwent testing with a Sequenom NIPT and whose pregnancies should have outcome based upon gestational age at the time of testing.

Ages

18 years and older

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject was pregnant and received NIPT from Sequenom/Integrated Genetics * Subject was 18 years of age or older at the time of NIPT * Pregnancy outcome is available Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pregnancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pregnancy

Contacts and locations

Locations

  • Integrated Genetics

    Westborough, Massachusetts, 01581, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.